Latest From Gene Therapy & Regenerative Medicine
Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.
Japanese firm backs off potential acquisition of Australian cell therapy venture after the two sides fail to agree on deal terms.
The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.
Company boosted by animal study which helps answer riddle of improvement in untreated eye.
Audentes Therapeutics is aiming for regulatory submissions next year for its lead product, a skeletal muscle-targeted gene therapy, which continues to show promise in X-linked myotubular myopathy.
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.